Inspiring Leaders, Outstanding Contributors
Novartis Alumni have inspiring stories and we applaud their achievements and personal growth as they continue to make an impact on business, society and human health.
Thousands of terminally ill oncology patients were touched by the contribution of Novartis Alumni Pascal Touchon during his 4 year tenure at Novartis. Familiar to many Novartians, Pascal started as a member of the Oncology Executive Committee leading the oncology BD&L and Strategy team with many achievements including the acquisition of crizanlizumab (Adakveo) and that of AAA. Then Pascal led the cell and gene franchise which helped get Kymriah approved and launched in the US, Europe, Canada, Australia and Japan.
In 2019 Pascal joined US based biotech Atara Biotherapeutics as CEO & President. With a focus on allogeneic T-cell immunotherapy, Atara allows Pascal to remain focused on patients with serious diseases and on transforming lives. The business of ‘life’ can be hard and complex requiring resilience and passion which Novartis taught him. Welcome to the Novartis Alumni Pascal it’s great to connect with you again.
Isabel Afonso, a familiar face to many of you, worked in 9 different roles during her 16 years with Sandoz and Novartis. Today, Isabel is the Chief Commercial Officer for US based company Performance Health, Private Equity owned and the largest global manufacturer and distributor of products to the rehabilitation and sports medicine markets. A life-long learner, Isabel has always looked for growth opportunities, and believes that investing in oneself is important. With a background in IT, Isabel holds qualifications from Harvard, Wharton and a General Management program from INSEAD. She’s even learning Mandarin, Genetics and Genomics at Stanford Medical School so that she can continue to develop and make progress for long term impact.
Isabel reflected that as a result of her time and positive experiences at Novartis, she is able to identify what ‘excellence’ looks like and what it takes to get there. Good to see you again Isabel and welcome to the Novartis Alumni!
Between 2005 and 2010 Richard Saynor held several regional leadership roles with Sandoz. He left Sandoz in 2010 to take up a global leadership role at GSK heading their classic and established medicines division based in Singapore. Even though Richard left Sandoz, he took with him a deep love for the company and its purpose - to pioneer access for patients - and when after eight years the opportunity arose to return to the company as CEO, he jumped at the chance. On his first day addressing Sandoz as the new CEO, he told the assembled associates that "this is my dream job." Returning to Sandoz was a big step, and Richard brought with him a wealth of experience and a bold ambition: to make Sandoz both a market leader and thought leader, encouraging a “generic mindset” and increasing patients’ access to therapy as a vital part of the overall Novartis purpose of reimagining medicine.
Under his leadership, 75% of all the medicines supplied by Novartis are Sandoz medicines and includes biosimilars and generic cancer therapies. Richard was behind critical moves to secure patient access during 2020 including an industry-leading pledge to keep prices stable for many essential medicines during the Coronavirus Pandemic and with the announcement of a joint investment to secure the long-term future of antibiotics manufacturing in Europe. This resulted from Sandoz's intensive efforts to broker an unprecedented cross-sector initiative that will maintain supplies of critical medicines to customers and patients worldwide.
Welcome back to the Novartis family Richard!